Ticagrelor with or without Aspirin in High-Risk Patients after PCI

In this placebo-controlled trial, 7119 patients were randomly assigned at 3 months after PCI to either receive ticagrelor alone or continue dual therapy with ticagrelor plus aspirin. The trial evaluated bleeding and ischemic end points at 1 year.

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 381; no. 21; pp. 2032 - 2042
Main Authors: Mehran, Roxana, Baber, Usman, Sharma, Samin K, Cohen, David J, Angiolillo, Dominick J, Briguori, Carlo, Cha, Jin Y, Collier, Timothy, Dangas, George, Dudek, Dariusz, Džavík, Vladimír, Escaned, Javier, Gil, Robert, Gurbel, Paul, Hamm, Christian W, Henry, Timothy, Huber, Kurt, Kastrati, Adnan, Kaul, Upendra, Kornowski, Ran, Krucoff, Mitchell, Kunadian, Vijay, Marx, Steven O, Mehta, Shamir R, Moliterno, David, Ohman, E. Magnus, Oldroyd, Keith, Sardella, Gennaro, Sartori, Samantha, Shlofmitz, Richard, Steg, P. Gabriel, Weisz, Giora, Witzenbichler, Bernhard, Han, Ya-ling, Pocock, Stuart, Gibson, C. Michael
Format: Journal Article
Language:English
Published: United States Massachusetts Medical Society 21.11.2019
Subjects:
Acute coronary syndromes
Aged
Antiplatelet therapy
Aspirin
Aspirin - adverse effects
Aspirin - therapeutic use
Bleeding
Cardiovascular disease
Cerebral infarction
Coronary Disease - drug therapy
Coronary Disease - therapy
Coronary vessels
Diabetes
Double-Blind Method
Drug Therapy, Combination
Female
Health risk assessment
Heart attacks
Hemorrhage
Hemorrhage - chemically induced
Humans
Inhibitor drugs
Ischemia
Kaplan-Meier Estimate
Male
Middle Aged
Mortality
Myocardial infarction
Myocardial Infarction - epidemiology
Percutaneous Coronary Intervention
Pharmaceuticals
Platelet Aggregation Inhibitors - adverse effects
Platelet Aggregation Inhibitors - therapeutic use
Risk Factors
Risk groups
Stents
Stroke
Stroke - epidemiology
Ticagrelor - adverse effects
Ticagrelor - therapeutic use
ISSN:0028-4793, 1533-4406, 1533-4406
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this placebo-controlled trial, 7119 patients were randomly assigned at 3 months after PCI to either receive ticagrelor alone or continue dual therapy with ticagrelor plus aspirin. The trial evaluated bleeding and ischemic end points at 1 year.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa1908419